Cell line · CVCL_0458
Papers35
1 to 20 of 35
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| IGF2R: a new player in the IGF2 loop sustaining adrenocortical carcinogenesis. | Cell Commun Signal | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The essential role of the redox balance in adrenal steroidogenesis. | Arch Endocrinol Metab | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Roflumilast Enhances Liraglutide's Atrial Natriuretic Peptide-Dependent Suppression of Adrenal Aldosterone Secretion. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| β-catenin functions as a molecular adapter for disordered cBAF interactions. | Mol Cell | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Defactinib in Combination with Mitotane Can Be an Effective Treatment in Human Adrenocortical Carcinoma. | Int J Mol Sci | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Emerging role of IGF1R and IR expression and localisation in adrenocortical carcinomas. | Cell Commun Signal | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Identification of CENPM as a key gene driving adrenocortical carcinoma metastasis via physical interaction with immune checkpoint ligand FGL1. | Clin Transl Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Therapeutic potential of targeting the FLNA-regulated Wee1 kinase in adrenocortical carcinomas. | Int J Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Development and Characterization of 3-Dimensional Cell Culture Models of Adrenocortical Carcinoma. | Endocrinology | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine Xenografts. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Discovery of a Cushing's syndrome protein kinase A mutant that biases signaling through type I AKAPs. | Sci Adv | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Oncogenic Wnt/β-Catenin Signaling in Adrenocortical Carcinoma Disrupts ECM Expression and Impairs Tumor Growth. | Cancers (Basel) | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Ketogenic diet promotes tumor ferroptosis but induces relative corticosterone deficiency that accelerates cachexia. | Cell Metab | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Classification of Cushing's syndrome PKAc mutants based upon their ability to bind PKI. | Biochem J | 2023 | Its Methods give the RRID and name the line | PubMed | |
| β-Catenin-Driven Differentiation Is a Tissue-Specific Epigenetic Vulnerability in Adrenal Cancer. | Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Preclinical Evidence of Progesterone as a New Pharmacological Strategy in Human Adrenocortical Carcinoma Cell Lines. | Int J Mol Sci | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Sublethal Hyperthermia Transiently Disrupts Cortisol Steroidogenesis in Adrenocortical Cells. | Endocrinology | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Mislocalization of protein kinase A drives pathology in Cushing's syndrome. | Cell Rep | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Mitotane Targets Lipid Droplets to Induce Lipolysis in Adrenocortical Carcinoma. | Endocrinology | 2022 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0458/papers